-- Clal Bio Surges Most in Two Weeks as Unit Gets FDA Approval
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-05-22T08:13:45Z
-- http://www.bloomberg.com/news/2012-05-22/clal-bio-surges-most-in-two-weeks-as-unit-gets-fda-approval.html
  Clal Biotechnology Industries Ltd. (CBI) 
advanced the most in two weeks after a unit got the U.S. Food
and Drug Administration orphan drug status for its DiaPep277
treatment for juvenile diabetes.  The  shares  of the investment company advanced 4.9 percent,
the most since May 8, to 13.06 shekels at 11:13 a.m. in Tel
Aviv.  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  